What Is Tesofensine?

1. How does tesofensine work?

Neurons release chemical messengers and then retrieve some of them through transporter proteins. Tesofensine blocks transporters for three monoamines: noradrenaline, also called norepinephrine, dopamine and serotonin. Blocking reuptake changes how long those signals remain available between cells.

These systems participate in appetite, reward and arousal. In a human PET study by Appel and colleagues, tesofensine occupied dopamine transporters in the brain, with greater occupancy at higher exposure. That establishes target engagement. The scan did not measure improved productivity, memory or motivation.

Research published by Perez and colleagues in 2024 examined feeding circuits in mice and rats. Tesofensine inhibited a subset of GABA-releasing neurons in the lateral hypothalamus, a brain region involved in feeding. The experiments help explain appetite suppression, but cannot establish a human fat-loss stack or cognitive benefit.

Tesofensine is a small molecule. Semaglutide and tirzepatide act through hormone receptors, while tesamorelin stimulates growth hormone release. Similar names and shared placement in peptide stores can obscure these different mechanisms.

2. Tesofensine weight-loss results and the Lancet warning

The 2008 Astrup trial randomized 203 adults with BMI 30–40 to tesofensine or placebo alongside an energy-restricted diet. Treatment lasted 24 weeks; 161 participants completed it.

The table preserves the paper’s placebo-adjusted results. These are percentage-point differences in body-weight loss, not each treatment group’s total loss.

Placebo participants lost 2.0% on average. Adding that to the reported 0.5 mg difference gives approximately 11.2% total loss. Quoting 9.2% without saying “beyond placebo” changes the meaning.

The Lancet Editors issued an expression of concern in 2013. A subsequent author correspondence addressed under-reporting of adverse effects. The concern remains attached to the publication record reviewed for this guide. An expression of concern is distinct from a retraction, but it prevents treating this paper as an uncomplicated validation of either efficacy or safety.

The trial population also limits the inference. Adults with obesity on a calorie-restricted diet cannot establish what a lean lifter would lose, how much muscle they would retain, or whether training performance would improve.

3. What other human studies add

The studies below ask different questions. An appetite follow-up from the same trial program is not an independent replication of its weight-loss result.

A separate Phase 3 program tested two tesofensine doses in 372 people over 24 weeks, according to Saniona’s August 2026 report. Saniona describes the study as successful. This review did not identify a full peer-reviewed publication from that trial, so its sponsor summaries should be labeled as such.

The UMIN registry entry lists first enrollment in August 2017 and registration in May 2024. That late registration limits its value for independently checking whether outcomes were specified before researchers saw the results.

4. Does tesofensine burn fat or mainly reduce appetite?

The two-week metabolic study found greater fullness and satiety. Total 24-hour energy expenditure did not increase significantly versus placebo. Nighttime expenditure was 4.6% higher after adjustment for body-composition changes, and measured fat oxidation increased by 18 grams per day.

Fat oxidation means using fat as fuel during the measurement period. It does not translate directly into that much extra body-fat loss every day: food intake, fat storage and expenditure across the rest of the day also affect the balance. This small, short study cannot support a promise of sustained “metabolic acceleration.”

The appetite follow-up found that satiety scores rose at week 12, then diminished as weight loss continued. Scores returned to baseline after withdrawal and rose again with treatment reintroduction. The authors could not determine whether the fading effect reflected adaptation to weight loss or a diminishing drug effect.

For readers interested in “food noise,” these questionnaires are relevant to hunger and fullness. They did not establish a permanent reset of appetite or a validated treatment for every form of compulsive eating. The uncontrolled extension also cannot resolve long-term efficacy by itself.

5. Tesofensine half-life and accumulation

A public Saniona clinical protocol reports a human elimination half-life of about 220 hours, roughly nine days. Its active metabolite, NS2360, lasts longer, about 374 hours. A separate population pharmacokinetic analysis by Lehr and colleagues estimated 234 hours for tesofensine and 374 for the metabolite using data from 320 subjects with Alzheimer’s disease. The estimates put elimination on a scale of days to weeks, with variation between people. Half-life does not set the interval between doses.

For illustration, a simple elimination model with a nine-day half-life leaves about half the parent drug after nine days, a quarter after 18 and an eighth after 27. Those are calculated fractions, not measured symptom durations or a safe washout schedule. Repeated dosing and the metabolite complicate the picture.

This makes a few uneventful days a poor test of eventual tolerability. Exposure builds with repeated use, and stopping does not remove it overnight. A half-life visualizer can illustrate that accumulation, but cannot predict a person’s concentration or clear them to combine medicines.

6. Side effects, heart rate and interactions

The 2008 paper reported dry mouth, nausea, constipation, hard stools, diarrhea and insomnia. At 0.5 mg, heart rate increased by 7.4 beats per minute; blood-pressure differences at 0.25 and 0.5 mg were not significant versus placebo. These observations come from the publication with the expression of concern, including questions about adverse-event reporting.

A lack of statistical significance in a short trial cannot establish cardiovascular safety over years. The research reviewed here does not supply a large cardiovascular-outcomes trial showing what happens to heart attacks, strokes or cardiovascular deaths.

Sleep and psychiatric effects also appear in the separate Tesomet trial. Sleep disturbances occurred in 50% with Tesomet versus 13% with placebo. One participant stopped treatment after a serious adverse event involving worsened pre-existing anxiety. These are combination-treatment observations in a small sample, not dependable incidence estimates for tesofensine alone.

The TM003 protocol prohibited several concomitant medicines, including MAO inhibitors, SSRIs, SNRIs and other appetite suppressants. Those exclusions do not quantify every interaction, but they limit what the trial can say about combinations. A medication review needs to include antidepressants, stimulants and supplements; abruptly stopping prescribed treatment to make room for tesofensine is not a substitute for that review.

7. What is Tesomet, and does metoprolol solve the heart-rate problem?

Tesomet is an investigational fixed-dose combination of tesofensine and metoprolol, a beta-1 blocker. Researchers paired them to reduce tesofensine’s cardiovascular effects while retaining appetite suppression. Saniona’s development page describes this rationale and says the Phase 2b programs were paused for funding reasons.

In the 21-person hypothalamic-obesity trial, Tesomet produced an additional 6.3 percentage points of weight loss versus placebo over 24 weeks. Heart-rate and blood-pressure differences between groups were not significant. Hypothalamic obesity follows injury to brain systems controlling energy balance, so the result cannot be generalized directly to ordinary obesity or a bodybuilding cut.

That trial was too small to establish protection against uncommon cardiovascular events. It also cannot validate adding a beta blocker to an online tesofensine product. Changing pulse is one outcome; establishing the safety of a combination requires broader evidence.

8. Tesofensine vs semaglutide, tirzepatide and tesamorelin

The comparisons start with what each compound targets and what its studies measured.

The phrase “twice the weight loss of approved drugs” originated in an older treatment landscape. It cannot be carried forward as a demonstrated advantage over modern semaglutide or tirzepatide regimens. Comparing percentages from separate trials also requires matching duration, population and whether placebo has been subtracted.

This review did not identify controlled human evidence establishing a tesofensine stack with tirzepatide, semaglutide or retatrutide. Different mechanisms make a combination a research question. They do not establish added benefit, tolerability or a dose ratio.

9. Is tesofensine approved, and what does that mean for dosage?

As checked on September 21, 2026, the sources reviewed describe tesofensine as investigational. In its August 27 report, Saniona says Medix continues to pursue regulatory approval. The report calls Mexico’s February 2023 committee opinion favorable and non-binding. It does not report a marketing authorization.

The FDA orphan-drug record for tesofensine plus metoprolol lists the combination as not approved for its orphan indication. Orphan designation supports development for a rare condition; it does not authorize sale or establish general weight-loss safety.

The research doses above describe what investigators tested. They do not establish a starting dose, cycle, titration or maintenance plan for healthy adults. Likewise, a capsule labeled with the same milligram amount as a trial does not establish equivalent identity, formulation or exposure.

For someone documenting exposure to discuss with a clinician, useful records include the exact product, dates, other medicines and supplements, appetite, sleep, resting pulse, blood pressure and symptoms. Weight alone would miss several of the tolerability problems the studies measured.

10. Tesofensine FAQ

• Is tesofensine a peptide?

  No. Tesofensine, also called NS2330, is a small-molecule monoamine reuptake inhibitor studied as an oral drug. Its appearance in peptide catalogs does not change its chemistry.

• Does tesofensine work for weight loss?

  Human trials reported weight loss, but the frequently cited 2008 trial carries a Lancet expression of concern. Later Phase 3 results are described by the sponsor; this guide did not identify a full peer-reviewed report of that study.

• What is tesofensine's half-life?

  A public clinical protocol reports about 220 hours, or nine days, for tesofensine and about 374 hours for its active metabolite NS2360. These estimates describe elimination, not a dosing interval or the duration of appetite suppression.

• What tesofensine dosage has been studied?

  The 24-week 2008 obesity trial tested 0.25, 0.5 and 1 mg orally once daily. These are research doses from a publication with an expression of concern, not an established regimen for self-directed use.

• Is tesofensine FDA-approved or approved in Mexico?

  Tesofensine remains investigational in the sources reviewed for this September 2026 guide. Saniona's August 2026 report says Medix is pursuing approval in Mexico. The 2023 favorable committee opinion was non-binding; FDA orphan designation for Tesomet is also not approval.

• Can tesofensine be stacked with tirzepatide or retatrutide?

  This review did not identify controlled human trials establishing the added benefit or safety of those combinations. Acting on different pathways does not establish a safe stack, dose ratio or schedule.

• Is tesofensine the same as tesamorelin?

  No. Tesofensine affects monoamine reuptake and appetite. Tesamorelin is a growth hormone-releasing hormone analogue with a specific approved use for excess abdominal fat in adults with HIV-associated lipodystrophy.

• Is tesofensine a nootropic?

  Effects on dopamine transporters do not establish better focus, memory or motivation in healthy people. The evidence reviewed here does not establish tesofensine as a cognitive enhancer or ADHD treatment.

11. Sources